REMEVi explains its new, lower compounded GLP-1 prices and what stayed the same, in a three-minute briefing
LAS VEGAS — November 11, 2026 — This is a short briefing from REMEVi, a bilingual telehealth platform for GLP-1 weight-loss care, about its new, lower prices for compounded semaglutide and tirzepatide. It takes about three minutes.
First, the prices. At REMEVi, compounded semaglutide now starts at $96 a month on the 12-month plan, which is $1,248 paid up front. On the 6-month plan it is $118 a month, or $708 up front. On the 3-month plan it is $125 a month, or $375 up front. Month to month, it is $143.
Compounded tirzepatide now starts at $168 a month on the 12-month plan, which is $2,184 paid up front. On the 6-month plan it is $199 a month, or $1,194 up front. On the 3-month plan it is $215 a month, or $645 up front. Month to month, it is $224.
Compounded oral semaglutide is $163 a month on the 6-month plan, $170 a month on the 3-month plan, or $215 month to month.
A plan month is one 28-day supply, and the 12-month plan is a 52-week term with 13 fills. These prices apply to new plans started on or after November 10, 2026.
Second, why lower them. Cost is the most common barrier to this kind of care. In a KFF Health Tracking Poll published in November 2025, 56% of adults who had used a GLP-1 medication said it was difficult to afford, and 14% said they had stopped because of the cost. Language is the other barrier. More than 40 million people in the United States speak Spanish at home, according to the U.S. Census Bureau, and the CDC's most recent national survey puts adult obesity prevalence at 44.0% among Hispanic adults, compared with 40.3% for all adults.
Third, what did not change. Every plan is still one price at every dose, so the price does not rise when the dose does. There is no membership fee. The plan price covers the evaluation by a licensed clinician, the medication if it is prescribed, labs when the clinician requires them, supplies and shipping.
Fourth, the safeguards. REMEVi is LegitScript certified, certification ID 50384507. A prescription is required, and every patient is reviewed by a clinician licensed in the patient's state. Medications are prepared by state-licensed 503A compounding pharmacies in the United States, and REMEVi names them on its website. The program is available in 49 states and Washington, D.C. It is not available in Louisiana.
Fifth, language. The website, the health questionnaire, messages and care coordination are available in Spanish and in English, at the same prices.
Blake Chapman, co-founder of REMEVi, put it this way: "Price and language are the two things that keep people out of this kind of care. When the medication costs too much, people look for shortcuts. When nobody on the other end speaks your language, you are guessing about your own treatment. We lowered our prices and kept everything else the same: a licensed clinician reviews every patient, the pharmacies are state-licensed and named on our site, and all of it works in Spanish as well as it does in English."
Every figure in this briefing is published at remevihealth.com/pricing, and in Spanish at remevihealth.com/es/precios.
About REMEVi
REMEVi is a bilingual telehealth platform based in Las Vegas, Nevada, offering GLP-1 weight-loss care and clinician-prescribed wellness therapies in English and Spanish in 49 states and Washington, D.C. REMEVi was founded in 2026 by Blake Chapman and Danai Del Carmen Chapman.
Compounded medications are not FDA-approved. A prescription from a licensed clinician is required, and eligibility is determined by the clinician. Plans renew at the same price until canceled. Prices are in U.S. dollars and were current on November 10, 2026.